Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Feb 12 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab forecast 2026 revenue largely in line with analysts estimates on Thursday, as the drugmaker bets on growth for its cystic fibrosis ...

Christopher Young: Welcome everyone and thank you for joining us. It's great to join you on my first earnings conference call as President and CEO of Vertex. Our financial results for the fourth ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Thursday afternoon. Here’s what you need to know. Vertex Pharmaceuticals met analysts’ revenue expectations last ...

Vertex has delivered earnings growth over the past decade thanks to its leadership in cystic fibrosis treatment. In recent years, the company has launched products in other treatment areas too. On top ...